CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Timoptic in Ocudose

timolol maleate· ingredient timololBeta blocking agents· TIMOLOL MALEATE 3.4 mg/mL; TIMOLOL MALEATE 6.8 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$5.94
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other timolol products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
Timolol Maleate$0.75535−$5.19
timolol maleate$0.79615−$5.15
COSOPT$0.92983−$5.01
COSOPT PF$1.08−$4.86
Timolol maleate$1.60−$4.34
Brimonidine Tartrate/Timolol Maleate$2.38−$3.56
Timolol GFS$13.33+$7.39
TIMOLOL MALEATE$13.33+$7.39

Medicare Part D coverage · CY2026

On 19 plan formularies · typical tier 4
Prior auth 5% · Step therapy 0% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.